Worldwide Kidney Cancer Diagnostics and Therapeutics Industry to 2026 - Endorsement of Novel Drugs for Treatment is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Kidney Cancer Diagnostics and Therapeutics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering.
The global kidney cancer diagnostic and therapeutic market are growing at a considerable CAGR of 6.8% during the forecast period.
- Abbvie, Inc.
- Active Biotech Ab
- Actuate Therapeutics, Inc.
- Adaptimmune Therapeutics Plc
- AstraZeneca Plc
- Bayer AG
- Cipla Limited
- Eisai Co., Ltd.
- Exelixis, Inc.
- . Genentech, Inc.
- GlaxoSmithKline Plc
- Hoffman-La Roche, Ltd.
- Jazz Pharmaceuticals, Inc.
- Merck & Co.
- Novartis AG
- Pfizer, Inc.
- Prometheus Laboratories, Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Co., Ltd.
The key features that drive the market growth include, increasing prevalence of kidney cancer, change in lifestyles such as smoking and drinking, less physical activity, and endorsement of novel drugs for the treatment of kidney cancer are the main factors driving the growth of the kidney cancer diagnostic and therapeutic market. In addition, for marketers, immunotherapies would rise as an opportunity in the market. Endless modernization in technological development and drug expansion in different therapies such as immunotherapy, and chemotherapy is expected to drive the growth of the global kidney cancer market. Development in treatment therapy such as immunotherapy is projected to generate huge prospects for the market.
Immunotherapy has less injurious than chemotherapy which creates it more suitable for senior people. Immunotherapy demonstrates a fast and constant reaction as compared to chemotherapy. an enormous number of the undiagnosed patient base in unused geographies will likely create profitable opportunities for the market dealers. However, growing preference for generic drugs and extraordinary costs related to branded drugs to treat kidney cancer are expected to restraint the market growth in the upcoming future.
The global kidney cancer diagnostic and therapeutic market is segmented based on Therapy type, diagnosis method, and cancer type. Based on therapy type, the market is segmented into targeted therapy, immunotherapy, and cryoablation. Immunotherapy drug combinations, the combination of immune therapies with directed therapies, and directed therapies are now usually the first-line option to cure kidney cancers that cannot be separated by surgery or have spread outside the kidney. More research is being done to see which people with kidney cancer will benefit most from targeted therapy, immunotherapy, or combinations. According to the American cancer society, Initial studies seem to show that they do not respond as well to targeted therapy drugs and appear to have poorer outcomes. Cancer rates could further increase by 50%, to 15 million new cases by 2020, as per the World Cancer Report. It also delivers a clear indication that healthy lifestyles and public health action by governments and health specialists could stem this trend and prevent as many as one-third of cancers, globally.
The global kidney cancer diagnostic and therapeutic market is analyzed based on the geographical regions that are contributing significantly to the growth of the market. The market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific) and Rest of the World (RoW). North America is estimated to contribute a significant share in the global kidney cancer market. North America has one of the highest market shares in the global kidney cancer market in terms of revenue as the increase in government initiatives for the enhancement of healthcare facilities in the region. North America has more patients suffering from cancer and chronic diseases as compared to other regions that will increase regional growth. Europe has projected to contribute considerable revenue share in the global kidney cancer market, and the Asia Pacific is expected to have the fastest growth in terms of revenue, due to the increase in the number of patients having chronic diseases, the prevalence of kidney cancer, and an increase in government inventiveness for the enhancement of healthcare facilities in the region.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global kidney cancer diagnostic and therapeutic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying 'who-stands-where in the market.
Key Topics Covered:
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
18.104.22.168. Financial Analysis
22.214.171.124. SWOT Analysis
126.96.36.199. Recent Developments
4. Market Determinants
5. Market Segmentation
6. Regional Analysis
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/utt16b
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900